The Impact of Symptom Severity on the Cost of Alzheimer's Disease-Reference-Cited by-同舟云学术

The Impact of Symptom Severity on the Cost of Alzheimer's Disease

Published:2002-02 Issue:2 Volume:50 Page:321-327
ISSN:0002-8614
Container-title:Journal of the American Geriatrics Society
language:en
Short-container-title:Journal of the American Geriatrics Society

Author:

Small Gary W.¹²³⁴⁵,McDonnell Diana D.⁶,Brooks Rachelle L.⁶,Papadopoulos George⁷

Affiliation:

1. Center on Aging

2. The Alzheimer's Disease Center

3. The Neuropsychiatric Institute

4. Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, California;

5. The VA Greater Los Angeles Healthcare System, Los Angeles, California;

6. Consumer Health Sciences, Princeton, New Jersey; and

7. Janssen Pharmaceutica Products LP, Titusville, New Jersey.

Publisher

Wiley

Subject

Geriatrics and Gerontology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1532-5415.2002.50065.x

Reference32 articles.

1. Chronic Care Costs In Managed Care

2. Opportunities for improving managed care for individuals with dementia: Part 1—The issues.;Fillit H;Am J Manag Care,1999

3. Alzheimer's Disease Under Managed Care: Implications from Medicare Utilization and Expenditure Patterns

4. The US economic and social costs of Alzheimer's disease revisited.

5. The economic cost of Alzheimer's disease and related dementias to the California Medicaid program (“Medi‐Cal”) in 1995.;Menzin J;Am J Geriatr Psychiatry,1999

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ascertaining Out-of-Pocket Costs of Dementia Care: Feasibility of A Weekly Online Survey-based Approach (Preprint);JMIR Formative Research;2024-01-31

2. Ascertaining Out-of-Pocket Costs of Dementia Care: A weekly Online Survey-based Approach (Preprint);2024-01-31

3. Cost structure in specialist mental healthcare: what are the main drivers of the most expensive episodes?;International Journal of Mental Health Systems;2023-11-09

4. Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation;Neurology and Therapy;2023-05-15

5. A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial;Neurology and Therapy;2023-04-02